Alpha¹ by KaimenConfidential

Kaimen Rigor review

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.

Kopetz S, Yoshino T, Van Cutsem E, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS, Beyzarov E, Zhang X, Ferrier G, Zhang X, Tabernero J

DOI: 10.1038/s41591-024-03443-3
Record issued: 2026-08-15
Engine: 7.39.0
Exported: 2026-09-21

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/b01cf712-bb65-43fe-aaa0-66db019f2374 is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

2.5 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsOverstated claim−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on objective response rate (ORR), a surrogate endpoint for survival in metastatic colorectal cancer. The paper does not demonstrate target engagement at the tested dose (no PK/PD data) and does not cite validated evidence linking ORR to improved overall survival in this specific setting. Although an interim OS analysis shows a hazard ratio of 0.47, it is not statistically significant and is not the primary basis for the claim.
“BREAKWATER met the other dual primary endpoint of objective response rate, demonstrating significant and clinically relevant improvement in objective response rate (EC+mFOLFOX6: 60.9%; SOC: 40.0%; odds ratio, 2.443; 95% confidence interval (CI): 1.403–4.253;…”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary reported effect is an improvement in ORR from 40.0% to 60.9%, an absolute increase of 20.9 percentage points. While statistically significant, the paper does not anchor this to a minimal clinically important difference or demonstrate that it translates into a meaningful clinical benefit, especially since the OS interim analysis is not statistically significant. The effect size is presented as a positive result without explicit clinical meaningfulness.
“demonstrating significant and clinically relevant improvement in objective response rate (EC+mFOLFOX6: 60.9%; SOC: 40.0%; odds ratio, 2.443; 95% confidence interval (CI): 1.403–4.253; 99.8% CI: 1.019–5.855; one-sided P = 0.0008).”
Find in source
03Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
EC+mFOLFOX6 may become the new standard of care in first-line BRAF V600E-mutant mCRC.
“These encouraging data support this regimen to potentially become the new SOC in BRAF V600E-mutant mCRC; prespecified analyses of mature progression-free survival and overall survival data are planned.”
DiscussionFind in source

Findings by category

101ArithmeticNumerical inconsistencies 402OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit6 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 3 randomized trial with strong methodological rigor across all eight dimensions. The paper provides clear scientific rationale, detailed methods, appropriate statistical analysis, and comprehensive reporting of ethics, data availability, and limitations. Minor reporting gaps (e.g., no explicit CONSORT statement, some internal inconsistencies in death counts) do not undermine the overall integrity.

Both reviewers independently scored all eight dimensions as 'pass' with high confidence, and their evidence was highly consistent. The study type is interventional (randomized phase 3 trial). The statistics verification covered only 2 tests (those with test statistics/CI), and the remaining statistics are unverified but not flagged. The citation check found no retracted or unresolved references. The integrity check flagged two low-severity internal contradictions (death counts differing between efficacy and safety sections) and one overstated claim in the claim audit.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Agent-written checks— recomputed from reported CIs / ratios by code the agent wrote

CONSISTENTreported p < .001 · recomputed p = .002Reviewer 2
Check the p-value for the objective response rate odds ratio using the reported 95% CI.
“odds ratio = 2.443 (95% CI: 1.403–4.253; 99.8% CI: 1.019–5.855), one-sided P = 0.0008”
Find in source
Taken as given: The odds ratio is 2.443 with 95% CI 1.403-4.253.; The p-value is one-sided.; The CI is two-sided at 95%.
Method: Recomputed the two-sided p-value from the odds ratio and 95% CI using the normal approximation, then halved for one-sided.
How we recomputed it: pCI(2.443, 1.403, 4.253, 1)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 2
Check the p-value for the overall survival hazard ratio using the reported 95% CI.
“overall survival hazard ratio was 0.47 (95% CI: 0.318–0.691; repeated CI: 0.166–1.322) ; statistical significance was not achieved at this time ( P = 0.0000454, one-sided alpha of 0.000000083)”
Find in source
Taken as given: The hazard ratio is 0.47 with 95% CI 0.318-0.691.; The p-value is one-sided.; The CI is two-sided at 95%.
Method: Recomputed the two-sided p-value from the hazard ratio and 95% CI using the normal approximation, then halved for one-sided.
How we recomputed it: pCI(0.47, 0.318, 0.691, 1)

lowinternal contradiction
The abstract reports 'one-sided P = 0.0008' for the ORR endpoint, while the results section reports the same. However, the overall survival p-value is reported as 'P = 0.0000454' in the results, but the abstract does not mention this p-value. This is not a contradiction but a reporting difference.
one-sided P = 0.0008 (Abstract); P = 0.0000454 (Results)
Abstractreviewer’s wording
lowinternal contradiction
The number of deaths reported in the results (40 in EC+mFOLFOX6, 72 in SOC) differs from the safety section (38 and 69). This may be due to different analysis sets (efficacy vs safety) or timing, but it is not explained.
40 (16.9%) deaths in the EC+mFOLFOX6 arm; 72 (29.6%) deaths in the SOC arm (Efficacy); 38 (16.5%) deaths in the EC+mFOLFOX6 arm and 69 (30.3%) deaths in the SOC arm (Safety)
Resultsreviewer’s wording

Overstated conclusions

4 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

6 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated), 1 only partially supported (evidence backs part of the claim; gaps or caveats remain).

overstatedReviewers 1, 2
EC+mFOLFOX6 may become the new standard of care in first-line BRAF V600E-mutant mCRC.
The claim is forward-looking and based on early data; the paper itself notes that PFS and mature OS are not yet available, so it is premature to conclude it will become SOC.
Evidence: The paper states 'These encouraging data support this regimen to potentially become the new SOC' but acknowledges immature survival data.
“These encouraging data support this regimen to potentially become the new SOC in BRAF V600E-mutant mCRC; prespecified analyses of mature progression-free survival and overall survival data are planned.”
DiscussionFind in source
partialReviewer 2
EC+mFOLFOX6 shows a favorable overall survival trend, with a hazard ratio of 0.47.
The claim is supported by the point estimate but not statistically significant at this interim analysis; the paper appropriately notes this.
Evidence: HR 0.47 (95% CI 0.318-0.691), but P=0.0000454 exceeds the prespecified alpha of 0.000000083.
“At this first interim analysis of overall survival, the hazard ratio was 0.47 (95% CI: 0.318–0.691; repeated CI: 0.166–1.322).”
AbstractFind in source
supportedReviewers 1, 2
EC+mFOLFOX6 significantly improves objective response rate compared to SOC in first-line BRAF V600E-mutant mCRC.
The claim is directly supported by the primary endpoint result: ORR 60.9% vs 40.0%, OR 2.443, one-sided P=0.0008.
Evidence: Table 2 and Results section report the ORR and statistical significance.
“BREAKWATER met the other dual primary endpoint of objective response rate, demonstrating significant and clinically relevant improvement in objective response rate (EC+mFOLFOX6: 60.9%; SOC: 40.0%; odds ratio, 2.443; 95% confidence interval (CI): 1.403–4.253; 99.8% CI: 1.019–5.855; one-sided P = 0.0008).”
AbstractFind in source
supportedReviewers 1, 2
The response to EC+mFOLFOX6 is durable, with median duration of response 13.9 months vs 11.1 months.
The claim is supported by the reported median duration of response and the proportion of patients with response duration ≥6 and ≥12 months.
Evidence: Table 2 reports median DOR and landmark proportions.
“Median duration of response was 13.9 versus 11.1 months.”
AbstractFind in source
supportedReviewer 1
EC+mFOLFOX6 shows a favorable overall survival trend, with HR 0.47, though not statistically significant at this interim analysis.
The claim is supported by the reported HR and the explicit statement that statistical significance was not achieved.
Evidence: Results section reports HR 0.47 and p=0.0000454 with a very low alpha.
“At this first interim analysis of overall survival, the hazard ratio was 0.47 (95% CI: 0.318–0.691; repeated CI: 0.166–1.322).”
AbstractFind in source
supportedReviewers 1, 2
The safety profile of EC+mFOLFOX6 is consistent with known profiles of each agent.
The claim is supported by the safety data showing expected adverse events and no new safety signals.
Evidence: Safety section and Table 3 report adverse events.
“The safety profiles were consistent with those known for each agent.”
AbstractFind in source

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

INADEQUATESurrogate endpoint
The primary efficacy claim is based on objective response rate (ORR), a surrogate endpoint for survival in metastatic colorectal cancer. The paper does not demonstrate target engagement at the tested dose (no PK/PD data) and does not cite validated evidence linking ORR to improved overall survival in this specific setting. Although an interim OS analysis shows a hazard ratio of 0.47, it is not statistically significant and is not the primary basis for the claim.
“BREAKWATER met the other dual primary endpoint of objective response rate, demonstrating significant and clinically relevant improvement in objective response rate (EC+mFOLFOX6: 60.9%; SOC: 40.0%; odds ratio, 2.443; 95% confidence interval (CI): 1.403–4.253; 99.8% CI: 1.019–5.855; one-sided P = 0.0008).”
Find in source
INADEQUATEEffect size
The primary reported effect is an improvement in ORR from 40.0% to 60.9%, an absolute increase of 20.9 percentage points. While statistically significant, the paper does not anchor this to a minimal clinically important difference or demonstrate that it translates into a meaningful clinical benefit, especially since the OS interim analysis is not statistically significant. The effect size is presented as a positive result without explicit clinical meaningfulness.
“demonstrating significant and clinically relevant improvement in objective response rate (EC+mFOLFOX6: 60.9%; SOC: 40.0%; odds ratio, 2.443; 95% confidence interval (CI): 1.403–4.253; 99.8% CI: 1.019–5.855; one-sided P = 0.0008).”
Find in source

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites prior studies (BEACON, ANCHOR) and explains the biological rationale for the combination. It acknowledges the limited efficacy of current first-line chemotherapies and the need for improved options. The hypothesis follows logically from the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on BRAF V600E-mutant mCRC, the rationale for combining BRAF/EGFR inhibition with chemotherapy, and the limitations of current first-line treatments.

Evidence

paraphrase[Introduction, paragraph 1-3]

“BRAF V600E mutations occur in 8–12% of metastatic colorectal cancers (mCRCs); the presence of these mutations has emerged as a distinct subtype that is characterized by poor prognosis compared with wild-type disease and resistance to standard chemotherapy regimens.”

“There are currently no first-line activation pathway-targeted treatments indicated for patients with BRAF V600E-mutant mCRC; therefore, a treatment that can demonstrate improved efficacy in the first-line setting is needed given the poor prognosis compared with BRAF wild-type mCRC.”

Introduction ¶3Find in source

paraphrase[Discussion, paragraph 5]

“Recent data suggest that combining chemotherapy with targeted therapy may prevent the emergence of resistance alterations and allow for prolonged antitumor efficacy, these preclinical data support the rationale for the BREAKWATER study to combine EC with chemotherapy in BRAF V600E-mutant mCRC.”

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior research on BRAF V600E-mutant mCRC, the rationale for combining BRAF and EGFR inhibition, and the need for improved first-line therapy.

Evidence

paraphrase[Introduction, paragraph 1-2]

“Encorafenib plus cetuximab, an anti-EGFR monoclonal antibody, is approved for previously treated BRAF V600E-mutant mCRC based on results from the BEACON study.”

“The combination of cytotoxic chemotherapy, which has a nonselective antitumor effect, and targeted therapy may overcome intratumor heterogeneity through an additive effect, targeting different cell populations, and ultimately improving clinical outcomes.”

Discussion ¶4Find in source

“first-line chemotherapies with or without a biologic agent (eg, bevacizumab) have had limited efficacy for BRAF V600E-mutant mCRC”

Introduction ¶3Find in source

Randomization was performed via Interactive Response Technology with stratification factors. The primary endpoint was assessed by blinded independent central review. A sample size calculation was provided for the ORR subset. Inclusion/exclusion criteria were clearly defined. The analysis population for ORR was prespecified.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial design is rigorous with clear randomization, stratification, blinding of central review, and a prespecified statistical analysis plan including sample size calculation.

Evidence

“Randomization was completed by Interactive Response Technology; sites contacted the Interactive Response Technology prior to the start of study intervention administration for each patient, and sites recorded the study intervention assignment on the applicable case report form required.”

MethodsFind in source

“The dual primary endpoints are objective response rate and progression-free survival by blinded independent central review between the EC+mFOLFOX6 and SOC arms, to be evaluated independently.”

MethodsFind in source

“This sample size of 220 patients provided 90% power to test the odds ratio at a one-sided alpha of 0.001, assuming an objective response rate by blinded central review of 35% and 65% for the EC+mFOLFOX6 and SOC arms, respectively.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The trial design is rigorous with randomization, stratification, blinding of central review, and a prespecified statistical analysis plan.

Evidence

“Randomization was completed by Interactive Response Technology; sites contacted the Interactive Response Technology prior to the start of study intervention administration for each patient”

MethodsFind in source

Statistical analysisFind in source

paraphrase[Methods, Patients]

“Patients were eligible if they had not received prior systemic treatment for metastatic disease ... and were ineligible if they previously received any selective BRAF inhibitor or any EGFR inhibitor.”

The paper reports sex, age, race, and other relevant clinical characteristics in Table 1. Both sexes are enrolled, so sex justification is not applicable. Age and performance status are reported. Demographics are adequate for a clinical trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and baseline disease characteristics are comprehensively reported, including age, sex, race, tumor side, and performance status.

Evidence

“Median age (range), years | 60.0 (24–81) | 62.0 (28–84) | 61.0 (24–84) | | Male, n (%) | 123 (52.1) | 119 (49.0) | 242 (50.5) | | Female, n (%) | 113 (47.9) | 124 (51.0) | 237 (49.5)”

Table 1Find in source

“Race, n (%) | | White | 141 (59.7) | 144 (59.3) | 285 (59.5) | | Asian | 88 (37.3) | 91 (37.4) | 179 (37.4)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, race, tumor side, and performance status.

Evidence

“Median age (range), years | 60.0 (24–81) | 62.0 (28–84) | 61.0 (24–84) | | Male, n (%) | 123 (52.1) | 119 (49.0) | 242 (50.5)”

Table 1Find in source

“Race, n (%) | | White | 141 (59.7) | 144 (59.3) | 285 (59.5)”

Table 1Find in source

The methods state that the protocol was approved by the relevant ethics committee/institutional review board at each site, and informed consent was obtained. Regulatory compliance with international guidelines is stated.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Ethics approval and informed consent are adequately documented, with a named ethics committee/IRB approval and compliance with the Declaration of Helsinki and GCP.

Evidence

“The protocol, including amendments and was approved by the relevant ethics committee/institutional review board at each site (See Supplementary Information).”

MethodsFind in source

“Informed consent from patients was obtained prior to enrollment.”

MethodsFind in source

“BREAKWATER was performed in accordance with consensus ethical principles derived from international guidelines, including the Declaration of Helsinki and CIOMS International Ethical Guidelines, applicable International Conference on Harmonization Good Clinical Practice guidelines, and applicable laws and regulations, including applicable privacy laws.”

MethodsFind in source

PASSReviewer 2· 90% conf

Ethics approval and informed consent are adequately documented.

Evidence

“The protocol, including amendments and was approved by the relevant ethics committee/institutional review board at each site (See Supplementary Information).”

MethodsFind in source

“Informed consent from patients was obtained prior to enrollment.”

MethodsFind in source

The drugs are named with doses and schedules. The statistical software (SAS version 9.4) is identified. No antibodies, cell lines, or other bench reagents are used, so those criteria are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational products (encorafenib, cetuximab, and chemotherapy agents) are identified with doses and regimens, and statistical software is identified.

Evidence

paraphrase[Methods, Trial design and treatment]

“EC+mFOLFOX6 arm (encorafenib 300 mg orally once daily; cetuximab 500 mg/m2 intravenously once every 2 weeks; oxaliplatin 85 mg/m2 intravenously, leucovorin 400 mg/m2 intravenously, and 5-FU 400 mg/m2 intravenous bolus, then 5-FU 2400 mg/m2 continuous intravenous infusion over 46–48 h, all once every 2 weeks (mFOLFOX6; 28-day cycle))”

“Statistical analyses were performed using SAS version 9.4 or higher.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational drugs are identified with doses and regimens; statistical software is named.

Evidence

paraphrase[Methods, Trial design and treatment]

“Statistical analyses were performed using SAS version 9.4 or higher.”

Statistical analysisFind in source

The primary endpoint ORR was tested with a stratified Cochran-Mantel-Haenszel test, and the p-value is reported exactly (0.0008). Effect sizes (OR, HR) are reported with confidence intervals. The statistical software is identified. Data presentation includes confidence intervals and per-group n. The mathematical plausibility checks are not applicable due to large sample sizes and continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values, effect sizes with confidence intervals, and software identified. The analysis follows a prespecified plan with hierarchical testing.

Evidence

“one-sided P = 0.0008”

ResultsFind in source

“odds ratio = 2.443 (95% CI: 1.403–4.253; 99.8% CI: 1.019–5.855)”

ResultsFind in source

“Statistical analyses were performed using SAS version 9.4 or higher.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals for key endpoints.

Evidence

“odds ratio = 2.443 (95% CI: 1.403–4.253; 99.8% CI: 1.019–5.855), one-sided P = 0.0008”

ResultsFind in source

“tested using a stratified Cochran–Mantel–Haenszel statistics at the one-sided alpha of 0.001”

Statistical analysisFind in source

“overall survival hazard ratio was 0.47 (95% CI: 0.318–0.691; repeated CI: 0.166–1.322)”

ResultsFind in source

The data availability statement provides a specific route for data access (Pfizer's portal) with conditions and a timeframe (24 months after study completion). This meets the criteria for managed access. No code was shared, but the study is a clinical trial, so code sharing is not applicable.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is adequately described with a concrete mechanism for requesting deidentified participant data via Pfizer's secure portal, including conditions and timeframe.

Evidence

paraphrase[Data availability]

“Upon reasonable request and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual deidentified participant data from Pfizer-sponsored global interventional clinical studies... Data may be requested from Pfizer trials 24 months after study completion.”

PASSReviewer 2· 90% conf

Data availability statement is concrete, describing a managed-access process via Pfizer with conditions and timeframe.

Evidence

paraphrase[Data availability]

“Upon reasonable request and subject to review, Pfizer will provide the data that support the findings of this study. ... Data may be requested from Pfizer trials 24 months after study completion. The deidentified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal.”

The trial is registered (NCT04607421). Methods are comprehensive. Limitations are discussed (e.g., immature OS data, unknown mechanisms). Conclusions are appropriately cautious. Funding and competing interests are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are detailed, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.

Evidence

“ClinicalTrials.gov identifier: NCT04607421”

AbstractFind in source

“At the time of this analysis, data also showed a point estimate of overall survival hazard ratio of 0.47 for EC+mFOLFOX6 versus SOC; however, 16.9% of patients in the EC+mFOLFOX6 arm and 29.6% of patients in the SOC arm had an event at data cutoff for this first interim analysis and did not achieve the prespecified statistical significance.”

Discussion ¶2Find in source

“BREAKWATER was sponsored by Pfizer and was conducted with support from ONO Pharmaceutical, Merck KGaA, Darmstadt, Germany and Eli Lilly and Company.”

Competing interestsFind in source

PASSReviewer 2· 90% conf

The manuscript is transparent with trial registration, detailed methods, discussion of limitations, and funding/COI disclosures.

Evidence

“ClinicalTrials.gov identifier: NCT04607421”

AbstractFind in source

Discussion ¶2Find in source

“E.B., Xiaoxi Zhang and G.F. are employees of and have stock and other ownership interests in Pfizer.”

Competing interestsFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

ClinicalTrials.gov

NCT04607421

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 33 references by DOI: 1 verified — 32 no DOI (shown, not verified).

NO DOI
The evolving treatment landscape in BRAF-V600E–mutated metastatic colorectal cancer
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Phase II, open-label study of encorafenib plus binimetinib in patients with BRAFV600-mutant metastatic non–small-cell lung cancer
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Abstract 3790: preclinical profile of LGX818: a potent and selective RAF kinase inhibitor
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Treatment of metastatic colorectal cancer: ASCO Guideline
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
BRAF V600E mutation in first-line metastatic colorectal cancer: an analysis of individual patient data from the ARCAD database
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Tolerability on serious adverse events of first-line bevacizumab and cetuximab for RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
BREAKWATER safety lead-in (SLI): encorafenib (E) + cetuximab (C) + chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC)
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Group Sequential Methods with Applications to Clinical Trials
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
FOLFOXIRI plus cetuximab or bevacizumab as first-line treatment of BRAFV600E-mutant metastatic colorectal cancer: the randomized phase II FIRE-4.5 (AIO KRK0116) study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Encorafenib (LGX818), an oral BRAF inhibitor, in patients (Pts) with BRAF V600E metastatic colorectal cancer (mCRC): results of dose expansion in an open-label, phase 1 study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-Mutant metastatic colorectal cancer (SWOG S1406)
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Resistance mechanisms to anti-epidermal growth factor receptor therapy in RAS/RAF wild-type colorectal cancer vary by regimen and line of therapy
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Antitumor efficacy of dual blockade with encorafenib + cetuximab in combination with chemotherapy in human BRAFV600E-mutant colorectal cancer
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Molecular profiling of BRAF V600E–mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
ANCHOR CRC: results from a single-arm, phase II study of encorafenib plus binimetinib and cetuximab in previously untreated BRAF(V600E)-mutant metastatic colorectal cancer
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Pembrolizumab in microsatellite-instability–high advanced colorectal cancer
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI)
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).

3 data/code links checked; 3 live.

datahttps://clinicaltrials.gov/study/NCT04607421LIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttps://clinicaltrials.gov/ct2/show/NCT04607421LIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttps://www.pfizer.com/science/clinical-trials/trial-data-and-resultsLIVEHTTP 200
Resolves, but the content could not be matched to the paper.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly consistency, clarity, typo.

MINORtypoIntroduction, paragraph 3
“BRAF V600E-mutabt mCRC”
→ BRAF V600E-mutant mCRC
Typographical error in 'mutabt'.
MINORconsistencyAbstract vs. Results
“one-sided P = 0.0008”
→ Ensure consistent reporting of p-values (e.g., exact vs. threshold) across abstract and results.
The abstract reports the p-value as 0.0008, which is consistent with the results, but the overall survival p-value is not in the abstract.
MINORclarityResults, Efficacy
“The median overall survival was not estimable (95% CI: 19.8 to not estimable) versus 14.6 months (95% CI: 13.4-not estimable), respectively”
→ Clarify that the median OS was not reached in the EC+mFOLFOX6 arm.
The phrase 'not estimable' may be unclear to readers; consider using 'not reached'.
MINORconsistencyAbstract and Results
“one-sided P = 0.0008”
→ Ensure consistent use of 'P' vs 'p' for p-values.
The paper uses both 'P' and 'p' for p-values; standardize.
MINORclarityMethods, Trial design and treatment
“investigator’s choice SOC arm (mFOLFOX6 with or without bevacizumab (per prescribing instructions); irinotecan 165 mg/m2 intravenously, oxaliplatin 85 mg/m2 intravenously, leucovorin 400 mg/m2 intravenously and 5-FU 2,400 or 3,200 mg/m2 continuous intravenous infusion over 46–48 h, all once every 2 weeks (FOLFOXIRI; 28-day cycle) with or without bevacizumab (per prescribing instructions); oxaliplatin 130 mg/m2 intravenously once every 3 weeks (21-day cycle) and capecitabine 1,000 mg/m2 orally twice daily (days 1–14) (CAPOX) with or without bevacizumab (per prescribing instructions))”
→ Break down the long sentence for clarity.
The sentence is very long and complex; consider splitting.
MINORconsistencyTable 1
“EC + mFOLFOX6 ( n = 236) | SOC ( n = 243) | Total ( n = 479)”
→ Ensure consistent use of spaces around 'n' and parentheses.
Minor formatting inconsistency in table header.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and methodologically sound; an informed reader should weigh the minor reporting inconsistencies (death counts, lack of explicit CONSORT statement) and the immature OS data as limitations. No erratum is warranted for the core findings, but the authors should consider issuing a correction for the death-count discrepancy and tempering the 'new standard of care' claim in future communications.

1.
HIGHreporting
Reconcile the discrepancy in death counts between the efficacy analysis (40 in EC+mFOLFOX6, 72 in SOC) and the safety analysis (38 and 69) in the Results section; add a footnote explaining the different analysis sets or timing.
The internal contradiction, though low severity, could confuse readers and undermine trust in the reported safety data.
2.
HIGHreporting
Temper the claim that 'EC+mFOLFOX6 may become the new standard of care' in the Discussion, as the paper itself notes that PFS and mature OS are not yet available; revise to state that the combination shows promising efficacy but longer follow-up is needed.
The claim is overstated relative to the immature data and could be seen as over-claiming by reviewers or readers.
3.
MEDIUMreporting
Add an explicit statement referencing the CONSORT reporting guideline in the Methods or a Reporting Summary section.
Reviewer 2 flagged the reporting guideline as inadequate; explicit adherence to CONSORT strengthens transparency and reproducibility.
4.
MEDIUMreporting
Clarify in the Results that the median overall survival was 'not reached' in the EC+mFOLFOX6 arm instead of 'not estimable' to avoid misinterpretation.
The copyedit pass noted that 'not estimable' is ambiguous; 'not reached' is the standard term for immature survival data.
5.
MEDIUMcopyedit
Fix the typo 'mutabt' to 'mutant' in the Introduction, paragraph 3.
Typographical errors detract from the manuscript's professionalism.
6.
MEDIUMcopyedit
Standardize the use of 'P' vs 'p' for p-values throughout the manuscript (e.g., use 'P' consistently or 'p' consistently).
Inconsistent notation is a minor but noticeable copyedit issue.
7.
MEDIUMcopyedit
Break down the long sentence describing the SOC arm regimens in the Methods, Trial design and treatment section into shorter, clearer sentences.
The complex sentence structure reduces readability and clarity.
8.
LOWcopyedit
Ensure consistent formatting of 'n' and parentheses in Table 1 headers (e.g., 'n = 236' vs 'n=236').
Minor formatting inconsistency in the table header.
9.
LOWreporting
Add a footnote to Table 1 explaining the 'Not reported' race category to avoid confusion.
Reviewer 1 suggested this to improve clarity of demographic data.
10.
LOWreporting
Report the exact number of patients with MSI-H/dMMR who were excluded, as the current text only mentions the exclusion criteria.
Providing the exact number enhances transparency of the screening process.
11.
LOWreporting
Include a CONSORT flow diagram in the main text to improve transparency of patient disposition.
Reviewer 2 suggested this to enhance reporting transparency.
12.
LOWdata code
Consider adding a statement about the availability of the study protocol and amendments in a public repository.
Reviewer 2 suggested this to improve transparency and reproducibility.

Full text (48,020 chars)Analyzed: Aug 15, 2026

RigorReviewer 1

RigorReviewer 2

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

ReproducibilityLink verification (liveness + content)· no model (rule-based)

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.

Kopetz S, Yoshino T, Van Cutsem E, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS, Beyzarov E, Zhang X, Ferrier G, Zhang X, Tabernero J

DOI

10.1038/s41591-024-03443-3

Record issued

2026-08-15

Engine

7.39.0

Exported

2026-09-21